Skip to main content
All
Stories
Press Releases
Documents
Events
Statements
Other
Press shift tab to select search category
Loading...
Media
< Back
Media
Press Releases
Investors
Partnering
Careers
< Back
Careers
Careers
Working at Ipsen
Culture
All
Stories
Press Releases
Documents
Events
Statements
Other
Press shift tab to select search category
Loading...
United States
< Back
Global
Annual Report
Americas
Asia Pacific
Europe
United States
Brazil
Canada
Mexico
Australia
China
Singapore
South Korea
Japan
Belgium
Ukraine
UK
Germany
France
Nordics
Greece
Italy
Netherlands
Spain
Poland
Russia
Czech Republic
Switzerland
Austria
Home
Company
< Back
Company
Who We Are
Leadership
Our History
Science
< Back
Science
Areas of focus
Products
Clinical Trials
R&D
Grant Requests
Investigator Sponsored Studies
Responsibility
< Back
Responsibility
Responsibility
Environment
People
Governance
Charitable Donations
Patients
< Back
Patients
Patients
Early Access Public Policy
Stories
Pipeline Phase:
Phase – lll
BYLVAY®
ELAFIBRANOR
TAZVERIK + R²
ONIVYDE®+ 5-FU/LV + OXALIPLATIN
CABOMETYX® + ATEZOLIZUMAB
X
You are now leaving the Ipsen US website. To continue, please click on
continue
.